DT-2216 | CAS#2365172-42-3 | Bcl-xL-specific degrader

MedKoo Cat#: 558958 | Name: DT-2216

Description:

WARNING: This product is for research use only, not for human or veterinary use.

DT2216 is discontinued for commercial reasons.

Chemical Structure

DT-2216

CAS#2365172-42-3 (free base)

Theoretical Analysis

MedKoo Cat#: 558958

Name: DT-2216

CAS#: 2365172-42-3 (free base)

Chemical Formula: C77H96ClF3N10O10S4

Exact Mass: 1540.5834

Molecular Weight: 1542.36

Elemental Analysis: C, 59.96; H, 6.27; Cl, 2.30; F, 3.70; N, 9.08; O, 10.37; S, 8.31

Price and Availability

Size	Price	Availability
5mg	USD 90.00	Ready to Ship
10mg	USD 150.00	Ready to Ship
50mg	USD 450.00	Ready to Ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

2365172-42-3 (free base) DT2216 HCl DT2216NC DT2216-isomer

Synonym

DT-2216; DT2216; DT 2216; DT2216 HCl,

IUPAC/Chemical Name

(2S,4R)-1-((S)-2-(7-(4-((R)-3-((4-(N-(4-(4-((4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)benzoyl)sulfamoyl)-2-((trifluoromethyl)sulfonyl)phenyl)amino)-4-(phenylthio)butyl)piperazin-1-yl)-7-oxoheptanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide

InChi Key

PXVFFBGSTYQHRO-REQIQPEASA-N

InChi Code

InChI=1S/C77H96ClF3N10O10S4/c1-51(53-18-20-55(21-19-53)70-52(2)82-50-103-70)83-73(96)66-44-61(92)48-91(66)74(97)71(75(3,4)5)85-68(93)16-12-9-13-17-69(94)90-42-36-87(37-43-90)35-33-59(49-102-62-14-10-8-11-15-62)84-65-31-30-63(45-67(65)104(98,99)77(79,80)81)105(100,101)86-72(95)56-24-28-60(29-25-56)89-40-38-88(39-41-89)47-57-46-76(6,7)34-32-64(57)54-22-26-58(78)27-23-54/h8,10-11,14-15,18-31,45,50-51,59,61,66,71,84,92H,9,12-13,16-17,32-44,46-49H2,1-7H3,(H,83,96)(H,85,93)(H,86,95)/t51-,59+,61+,66-,71+/m0/s1

SMILES Code

CC1(C)CCC(C2=CC=C(Cl)C=C2)=C(C1)CN3CCN(C4=CC=C(C(NS(=O)(C5=CC(S(C(F)(F)F)(=O)=O)=C(N[C@@H](CSC6=CC=CC=C6)CCN7CCN(C(CCCCCC(N[C@@H](C(C)(C)C)C(N8[C@@H](C[C@@H](O)C8)C(N[C@H](C9=CC=C(C%10=C(N=CS%10)C)C=C9)C)=O)=O)=O)=O)CC7)C=C5)=O)=O)C=C4)CC3

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

DT2216 is a potent and selective BCL-XL degrader based on PROTAC technology.

In vitro activity:

Four Bcl-xL-dependent TCL cell lines (i.e., MyLa, MJ, MAC2A, and L82) were tested and all of them expressed high levels of Bcl-xL and low levels of Bim (Fig. 1a) and were relatively resistant to conventional chemotherapy drugs, but were highly sensitive to DT2216 (EC50, 5–280 nM) (Fig. 1b and Table 1). In contrast, TCL lines (DL40, SMZ1, and FEPD) found to depend on Mcl-1 for survival by BH3 profiling expressed relatively higher levels of Mcl-1 and were resistant to DT2216 (EC50 > 10,000 nM) (Fig. (Fig. 1a and Table 1). Notably, the three lines resistant to DT2216 lacked expression of Bcl-xL (Fig. 1a). All 7 cell lines expressed variable levels of Bax, Bak, and Noxa and similar levels of VHL (Fig. 1a). As we previously showed, human platelets were highly sensitive to ABT263 but very resistant to DT2216 compared with Bcl-xL-dependent TCL cells because platelets express minimal levels of VHL to degrade Bcl-xL (Fig. 1b, Table 1, and Supplementary Fig. S1A, B). Reference: J Hematol Oncol. 2020 Jul 16;13(1):95. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/32677976/

In vivo activity:

DT2216 was compared to ABT263 in vivo by xenografting MyLa cells s.c. into immunodeficient mice. MyLa-engrafted mice were randomized into vehicle, ABT263 (50 mpk/qd/p.o.), or DT2216 (15 mpk/q4d/i.p.) treatment groups when their tumors reached ~ 100 mm3 (Fig. 2a). The dose of ABT263 used for this experiment was selected to avoid the ABT263 treatment-induced severe thrombocytopenia we observed in our recent study. One day after the first treatment, the blood was collected from each mouse for a CBC analysis. ABT263-treated mice had ~ 73% reduction in blood platelet counts compared to vehicle-treated mice, whereas DT2216-treated mice had ~ 16% reduction (Fig. 2b). Neither treatment significantly affected other blood cell counts (Fig. (Fig.2c,2c, d). Mice were continued on treatment until they became moribund or their tumors were close to 1000 mm3 or ulcerated. Neither ABT263 nor DT2216 significantly affected body weight (Fig. 2e). ABT263 treatment slightly slowed the tumor growth and moderately extended the median survival time of the mice (from 8 to 14.5 days) compared to vehicle treatment (Fig. 2f, g). In contrast, DT2216 treatment markedly suppressed the primary tumor growth and extended the median survival time of the mice to 29.5 days (Fig. 2f, g). More importantly, the marked tumor suppression induced by DT2216 was associated with a more than 95% reduction in Bcl-xL levels, substantial decreases in Bcl-2 and Mcl-1 levels, and significant activation of caspase-3 and cleavage of PARP in the tumors collected from the mice (Fig. 2h–m). The decreases in tumor expression of Bcl-2 and Mcl-1 after DT2216 treatment were likely due to the activation of caspase-3 and induction of MyLa cell apoptosis (as shown in Fig. 1c). In contrast, ABT263 treatment had no significant effect on the tumor expression of these Bcl-2 family proteins, nor did it induce significant activation of caspase-3 and cleavage of PARP in the tumors (Fig. 2h–m). These findings demonstrate that DT2216 is more potent against MyLa TCL cells but less toxic to platelets than ABT263 in mice. Reference: J Hematol Oncol. 2020 Jul 16;13(1):95. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/32677976/

	Solvent	mg/mL	mM
Solubility
	DMSO	20.0	12.97
	Ethanol	10.0	6.48

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 1,542.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

In vitro protocol:

1. He Y, Koch R, Budamagunta V, Zhang P, Zhang X, Khan S, Thummuri D, Ortiz YT, Zhang X, Lv D, Wiegand JS, Li W, Palmer AC, Zheng G, Weinstock DM, Zhou D. DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas. J Hematol Oncol. 2020 Jul 16;13(1):95. doi: 10.1186/s13045-020-00928-9. PMID: 32677976; PMCID: PMC7364785. 2. Khan S, Zhang X, Lv D, Zhang Q, He Y, Zhang P, Liu X, Thummuri D, Yuan Y, Wiegand JS, Pei J, Zhang W, Sharma A, McCurdy CR, Kuruvilla VM, Baran N, Ferrando AA, Kim YM, Rogojina A, Houghton PJ, Huang G, Hromas R, Konopleva M, Zheng G, Zhou D. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med. 2019 Dec;25(12):1938-1947. doi: 10.1038/s41591-019-0668-z. Epub 2019 Dec 2. PMID: 31792461; PMCID: PMC6898785.

In vivo protocol:

1: Negi A, Voisin-Chiret AS. Strategies to Reduce the On-Target Platelet Toxicity of Bcl-xL Inhibitors: PROTACs, SNIPERs and Prodrug-Based Approaches. Chembiochem. 2022 Mar 9:e202100689. doi: 10.1002/cbic.202100689. Epub ahead of print. PMID: 35263486. 2: Khan S, Wiegand J, Zhang P, Hu W, Thummuri D, Budamagunta V, Hua N, Jin L, Allegra CJ, Kopetz SE, Zajac-Kaye M, Kaye FJ, Zheng G, Zhou D. BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers. J Hematol Oncol. 2022 Mar 9;15(1):23. doi: 10.1186/s13045-022-01241-3. PMID: 35260176; PMCID: PMC8905794. 3: Thummuri D, Khan S, Underwood PW, Zhang P, Wiegand J, Zhang X, Budamagunta V, Sobh A, Tagmount A, Loguinov A, Riner AN, Akki AS, Williamson E, Hromas R, Vulpe CD, Zheng G, Trevino JG, Zhou D. Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL-Specific Degrader DT2216. Mol Cancer Ther. 2022 Jan;21(1):184-192. doi: 10.1158/1535-7163.MCT-21-0474. Epub 2021 Oct 19. PMID: 34667112; PMCID: PMC8742767. 4: He Y, Koch R, Budamagunta V, Zhang P, Zhang X, Khan S, Thummuri D, Ortiz YT, Zhang X, Lv D, Wiegand JS, Li W, Palmer AC, Zheng G, Weinstock DM, Zhou D. DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas. J Hematol Oncol. 2020 Jul 16;13(1):95. doi: 10.1186/s13045-020-00928-9. PMID: 32677976; PMCID: PMC7364785. 5: The PROTAC DT2216 Targets Cancer by Promoting BCL-XL Degradation. Cancer Discov. 2020 Feb;10(2):174. doi: 10.1158/2159-8290.CD-RW2019-185. Epub 2019 Dec 13. PMID: 34365411. 6: Khan S, Zhang X, Lv D, Zhang Q, He Y, Zhang P, Liu X, Thummuri D, Yuan Y, Wiegand JS, Pei J, Zhang W, Sharma A, McCurdy CR, Kuruvilla VM, Baran N, Ferrando AA, Kim YM, Rogojina A, Houghton PJ, Huang G, Hromas R, Konopleva M, Zheng G, Zhou D. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med. 2019 Dec;25(12):1938-1947. doi: 10.1038/s41591-019-0668-z. Epub 2019 Dec 2. PMID: 31792461; PMCID: PMC6898785.